- Home
- MDRR vs PHGE Comparison
MDRR vs PHGE Comparison
Compare MDRR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- PHGE
- Stock Information
- Founded
- MDRR 2015
- PHGE 2015
- Country
- MDRR United States
- PHGE Israel
- Employees
- MDRR N/A
- PHGE N/A
- Industry
- MDRR Real Estate Investment Trusts
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- PHGE Health Care
- Exchange
- MDRR Nasdaq
- PHGE Nasdaq
- Market Cap
- MDRR 18.0M
- PHGE 15.5M
- IPO Year
- MDRR 2018
- PHGE N/A
- Fundamental
- Price
- MDRR N/A
- PHGE $0.57
- Analyst Decision
- MDRR
- PHGE Strong Buy
- Analyst Count
- MDRR 0
- PHGE 1
- Target Price
- MDRR N/A
- PHGE $15.00
- AVG Volume (30 Days)
- MDRR 1.3K
- PHGE 379.7K
- Earning Date
- MDRR 11-11-2025
- PHGE 11-13-2025
- Dividend Yield
- MDRR 2.01%
- PHGE N/A
- EPS Growth
- MDRR N/A
- PHGE N/A
- EPS
- MDRR N/A
- PHGE N/A
- Revenue
- MDRR $9,649,145.00
- PHGE N/A
- Revenue This Year
- MDRR N/A
- PHGE N/A
- Revenue Next Year
- MDRR N/A
- PHGE N/A
- P/E Ratio
- MDRR N/A
- PHGE N/A
- Revenue Growth
- MDRR N/A
- PHGE N/A
- 52 Week Low
- MDRR $9.55
- PHGE $0.34
- 52 Week High
- MDRR $15.00
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- MDRR 52.34
- PHGE 55.95
- Support Level
- MDRR $13.13
- PHGE $0.57
- Resistance Level
- MDRR $13.99
- PHGE $0.65
- Average True Range (ATR)
- MDRR 0.10
- PHGE 0.05
- MACD
- MDRR -0.09
- PHGE 0.00
- Stochastic Oscillator
- MDRR 36.87
- PHGE 64.16
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).